New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 28, 2012
07:38 EDTCNDOCoronado Biosciences initiates Phase 1/2 trial of CNDO-109
Coronado Biosciences announced the initiation of a phase 1/2 dose escalation trial of allogeneic natural killer, or NK, cells activated by the Company's CNDO-109 in patients in first complete remission from acute myeloid leukemia, or AML, and who are deemed high-risk for relapse. The phase 1/2 trial is a multi-center, open-label, single-dose, dose-escalating clinical study designed to examine the safety of CNDO-109 activated allogeneic NK cells, as well as the relapse-free survival and overall survival in adult patients with AML. Up to 36 patients who are in CR1 from AML at the time of enrollment, and who are at high-risk for relapse, will be infused with a preparatory regimen of cyclophosphamide and fludarabine followed by a single dose of allogeneic NK cells activated by CNDO-109.
News For CNDO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 8, 2014
08:37 EDTCNDOCoronado forms subsidiary to acquire, license dermatology products
Coronado Biosciences has formed a wholly owned subsidiary, Journey Medical Corporation, or JMC, to acquire and license dermatology products. Under the leadership of Claude Maraoui, CEO, JMC will begin building a portfolio of dermatological assets focused on acne, steroid responsive dermatoses, pigmentation and antifungals for promotion to dermatologists and pediatricians.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use